Christophe Perruchoud
Research Subjects
Research Interests
Christophe Perruchoud has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Alessandra Calabrese
Neuromodulation Clinical Department, Medtronic, Tolochenaz, Switzerland
1 shared publicationBianca Papi
Neuromodulation Clinical Department, Medtronic, Maastricht, The Netherlands
1 shared publication- Cleo Mertz
Boston Scientific Neuromodulation, 1861 Brussels, Belgium
1 shared publication - David Abejón
Hospital Universitario Quironsalud Madrid
1 shared publication Denis Dupoiron
Anesthesiology and Pain Department, Institut de Cancérologie de l'Ouest, Paul Papin, Angers Cedex, France
1 shared publication- Hayat Belaid
Fondation Adolphe de Rothschild, 75019 Paris, France
1 shared publication
Latest Publications
- 1 January 2023
- Published by Springer Nature
- p. 597-604
Intrathecal Pharmacokinetics
- 21 January 2022
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 26 (6) , 1142-1152
Management of Cancer-Related Pain With Intrathecal Drug Delivery: A Systematic Review and Meta-Analysis of Clinical Studies
- 21 January 2022
- Published by Elsevier in Neuromodulation: Technology at the Neural Interface
- Vol. 26 (6) , 1142-1152
Management of Cancer-Related Pain With Intrathecal Drug Delivery: A Systematic Review and Meta-Analysis of Clinical Studies
- Open Access
- 10 September 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (18) , 4085
Real-World Outcomes Using a Spinal Cord Stimulation Device Capable of Combination Therapy for Chronic Pain: A European, Multicenter Experience
Given the differing mechanisms thought to underlie therapeutic sub- and supra-perception-based neurostimulative modalities, Spinal Cord Stimulation (SCS) systems designed for combined delivery of these approaches may help improve analgesic outcomes and quality of life, and reduce treatment failures. This multicenter, observational case-series evaluated 188 patients with chronic back and/or leg pain implanted with an SCS device capable of sequential or simultaneous delivery of sub-perception and supra-perception stimulation programming (i.e., combination therapy) at 16 sites in Europe. Following implantation, patients were provided with an array of advanced supra-perception programs (e.g., paresthesia-based SCS using multiple independent current sources), and a custom set of sub-perception programs optimized with specific waveforms and/or field shapes. A mean overall pain score of 7.9 ± 1.7 (Standard Deviation (SD)) was reported pre-trial (Baseline). Overall pain was reduced by 4.4 ± 2.8 points (NRS) at 3-months (n = 117) and at 12 months post-implant (n = 90), respectively (p < 0.0001). Substantial quality-of-life (EQ-5D-5L) improvement as assessed at last follow-up was also observed (n = 60). These results suggest that an implanted SCS device capable of combination therapy, while also enabled with patient-specific waveform optimization and stimulation field targeting capabilities, can enable highly effective pain relief and improve quality of life in patients suffering with chronic pain.
- 10 September 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (18) , 4085
Open AccessReal-World Outcomes Using a Spinal Cord Stimulation Device Capable of Combination Therapy for Chronic Pain: A European, Multicenter Experience
Given the differing mechanisms thought to underlie therapeutic sub- and supra-perception-based neurostimulative modalities, Spinal Cord Stimulation (SCS) systems designed for combined delivery of these approaches may help improve analgesic outcomes and quality of life, and reduce treatment failures. This multicenter, observational case-series evaluated 188 patients with chronic back and/or leg pain implanted with an SCS device capable of sequential or simultaneous delivery of sub-perception and supra-perception stimulation programming (i.e., combination therapy) at 16 sites in Europe. Following implantation, patients were provided with an array of advanced supra-perception programs (e.g., paresthesia-based SCS using multiple independent current sources), and a custom set of sub-perception programs optimized with specific waveforms and/or field shapes. A mean overall pain score of 7.9 ± 1.7 (Standard Deviation (SD)) was reported pre-trial (Baseline). Overall pain was reduced by 4.4 ± 2.8 points (NRS) at 3-months (n = 117) and at 12 months post-implant (n = 90), respectively (p < 0.0001). Substantial quality-of-life (EQ-5D-5L) improvement as assessed at last follow-up was also observed (n = 60). These results suggest that an implanted SCS device capable of combination therapy, while also enabled with patient-specific waveform optimization and stimulation field targeting capabilities, can enable highly effective pain relief and improve quality of life in patients suffering with chronic pain.